- Home
- KBDC vs ARVN Comparison
KBDC vs ARVN Comparison
Compare KBDC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBDC
- ARVN
- Stock Information
- Founded
- KBDC 2021
- ARVN 2015
- Country
- KBDC United States
- ARVN United States
- Employees
- KBDC N/A
- ARVN N/A
- Industry
- KBDC
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- KBDC
- ARVN Health Care
- Exchange
- KBDC Nasdaq
- ARVN Nasdaq
- Market Cap
- KBDC 1.2B
- ARVN 614.8M
- IPO Year
- KBDC N/A
- ARVN 2018
- Fundamental
- Price
- KBDC $15.65
- ARVN $6.81
- Analyst Decision
- KBDC Buy
- ARVN Buy
- Analyst Count
- KBDC 5
- ARVN 19
- Target Price
- KBDC $16.60
- ARVN $21.19
- AVG Volume (30 Days)
- KBDC 166.0K
- ARVN 3.3M
- Earning Date
- KBDC 05-12-2025
- ARVN 05-01-2025
- Dividend Yield
- KBDC 9.59%
- ARVN N/A
- EPS Growth
- KBDC N/A
- ARVN N/A
- EPS
- KBDC N/A
- ARVN N/A
- Revenue
- KBDC N/A
- ARVN $426,900,000.00
- Revenue This Year
- KBDC $193.84
- ARVN N/A
- Revenue Next Year
- KBDC $13.81
- ARVN N/A
- P/E Ratio
- KBDC N/A
- ARVN N/A
- Revenue Growth
- KBDC N/A
- ARVN 498.74
- 52 Week Low
- KBDC $13.93
- ARVN $5.94
- 52 Week High
- KBDC $17.99
- ARVN $37.38
- Technical
- Relative Strength Index (RSI)
- KBDC N/A
- ARVN 36.29
- Support Level
- KBDC N/A
- ARVN $6.23
- Resistance Level
- KBDC N/A
- ARVN $8.00
- Average True Range (ATR)
- KBDC 0.00
- ARVN 0.58
- MACD
- KBDC 0.00
- ARVN -0.07
- Stochastic Oscillator
- KBDC 0.00
- ARVN 16.81
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.